1669.4000 -3.10 (-0.19%)
NSE Jul 09, 2025 15:31 PM
Volume: 2.2M
 

1669.40
-0.19%
Motilal Oswal
Sun Pharmaceutical Industries (SUNP) delivered 4%/9%/4% miss on revenue/EBITDA/PAT for 4QFY25. Lower-than-expected sales in global specialty and ROW led to a miss on 4QFY25 performance.
Promoters pledged 0.19% of shares in last quarter. Total pledge stands at 0.88% of promoter holdings
More from Sun Pharmaceutical Industries Ltd.
Recommended